TY - JOUR
T1 - Thioridazine cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global trials is now!
AU - Amaral, Leonard
AU - Boeree, Martin J.
AU - Gillespie, Stephen H.
AU - Udwadia, Zarir F.
AU - van Soolingen, Dick
PY - 2010/6
Y1 - 2010/6
N2 - Thioridazine (TDZ) has been shown to have in vitro activity against multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains of Mycobacterium tuberculosis, to promote the killing of intracellular MDR and XDR strains and to cure the mouse of antibiotic-susceptible and -resistant pulmonary tuberculosis (TB) infections. Recently, TDZ was used to cure 10 of 12 XDR-TB patients in Buenos Aires, Argentina. At the time of writing, it is being used for the therapy of non-antibiotic-responsive terminal XDR-TB patients in Mumbai, India, on the basis of compassionate therapy and although it is too early to determine a cure, the patients have improved appetite, weight gain, are afebrile and free of night sweats, and their radiological picture shows great improvement. Because XDR-TB is essentially a terminal disease in many areas of the world and no new effective agents have yet to yield successful clinical trials, global clinical trials for the therapy of XDR-TB are urgently required. (C) 2010 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
AB - Thioridazine (TDZ) has been shown to have in vitro activity against multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains of Mycobacterium tuberculosis, to promote the killing of intracellular MDR and XDR strains and to cure the mouse of antibiotic-susceptible and -resistant pulmonary tuberculosis (TB) infections. Recently, TDZ was used to cure 10 of 12 XDR-TB patients in Buenos Aires, Argentina. At the time of writing, it is being used for the therapy of non-antibiotic-responsive terminal XDR-TB patients in Mumbai, India, on the basis of compassionate therapy and although it is too early to determine a cure, the patients have improved appetite, weight gain, are afebrile and free of night sweats, and their radiological picture shows great improvement. Because XDR-TB is essentially a terminal disease in many areas of the world and no new effective agents have yet to yield successful clinical trials, global clinical trials for the therapy of XDR-TB are urgently required. (C) 2010 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
KW - Pulmonary tuberculosis
KW - Multidrug-resistant TB
KW - Extensively drug-resistant TB
KW - NEW-YORK-CITY
KW - MYCOBACTERIUM-TUBERCULOSIS
KW - EMERGENCE
UR - http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6T7H-4YG7P4C-5&_user=1026342&_coverDate=06%2F30%2F2010&_rdoc=1&_fmt=high&_orig=search&_origin=search&_sort=d&_docanchor=&view=c&_acct=C000050565&_version=1&_urlVersion=0&_userid=1026342&md5=7e88d4633f91e520c4b91aecedfed090&searchtype=a
U2 - 10.1016/j.ijantimicag.2009.12.019
DO - 10.1016/j.ijantimicag.2009.12.019
M3 - Review article
SN - 0924-8579
VL - 35
SP - 524
EP - 526
JO - International Journal of Antimicrobial Agents
JF - International Journal of Antimicrobial Agents
IS - 6
ER -
